C4B and infection: Compared with the virus-infected group (Veh), CH pretreatment at 1.25, 2.5, and 5 mg/mL decreased A/PR/8/34-GFP infection in Raw264.7 cells by 16.9%, 38.3%, and 53%, respectively (Figure 1A).